(CNN) – A vacant China leader against the covid-19 developed by Sinovac Biotech has only 50.38% efficiency in last-stage stages in Brazil. This is a significantly higher percentage than the previous results, according to a statement published on March by the governor of Sao Paulo.
Even if the number exceeds the umbrella required for regulatory approval, this is due to the 78% pre-emptive ban, which generates doubts about the veracity of data and food skepticism about the lack of transparency with respect to vacancies.
Analysts say that the task force of the Coronavac of Sinovac in Brazil, the most dangerous among its global competitors, could affect the international confidence in the vacancies made in China and hinder the Beijing effort to repair its bad image temper the initial broth to proportion vacancies against the covid-19 for lands in development.
The Butantan Institute and the Governor of Sao Paulo inform that the vaccine against coronavirus increases a general efficacy rate of 50.38% in the clinical study conducted in Brazil, in addition to (an effective rate of) 78% for live cases and 100% for moderate and severe covid-19 cases. All the bags are more than the level of 50% required by the OMS (World Health Organization) », said the communiqué published on March.
It is probable that the stretch margin for regulatory approval generates preoccupation between the scientists, given that last week the Butantan Institute published partial results of “clinical efficacy” that celebrate an efficacy of 78% to 100% in infection prevention.
The state-of-the-art body is financing Phase 3 of the vaccine camps, in which 13,000 health workers participate in Brazilian states as well.
“In view of the general efficacy of the analysis, we will meet the requirements of the World Health Organization by 50.38%”, said March Ricardo Palacios, Director of Clinical Research at the Butantan Biomedical Center in Sao Paulo during a conference de prensa.
Without embarrassment, March, high-ranking members of the Ministry of Health of Brazil told CNN Brasil, CNN affiliate, that “efficiency is at the limit” and “because” is at the limit. We hope that ANVISA (Brazilian Health Regulatory Agency) will evaluate it ».
A representative of Sinovac says that the company is discussing the result, but has no further comments. The final efficacy case of the vaccine will be determined by the Chinese Medicines Regulator, the National Medical Production Administration, according to the representative.